GSK plc Sponsored ADR (GSK)
GSK names Luke Miels as CEO designate
British drugmaker GSK said on Monday it has appointed Luke Miels as CEO designate and he will assume full responsibilities as chief executive on January 1, 2026.
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.
GSK commits $30bn to US drug research and manufacturing
GSK PLC (LSE:GSK, NYSE:GSK) will pour $30 billion into research, development and manufacturing in the United States over the next five years, in one of the largest overseas investment programmes announced by a UK-listed company. The commitment includes a fresh $1.2 billion package unveiled today to expand production capacity and adopt artificial intelligence and digital technologies across its American operations.
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.
GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs
GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.
GSK plans $30 billion US investment as pharma tariff threat looms
GSK said on Wednesday it plans to invest $30 billion in research and development and supply chain infrastructure in the United States over the next five years, after U.S. President Donald Trump arrived in Britain for an unprecedented second state visit to seal investment deals.
GSK opens higher after priority review for new gonorrhoea pill
Shares in GSK PLC (LSE:GSK, NYSE:GSK) opened higher following the US Food and Drug Administration's acceptance of gepotidacin for priority review as an oral treatment for uncomplicated urogenital gonorrhoea. The decision, based on positive phase III data from the EAGLE-1 trial, sets a target FDA decision date of December 2025.
GSK to Receive $370 Million in U.S. Patent Litigation Settlement
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.
GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute
GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine technology. The deal will also see GSK collect a 1% royalty on United States sales of Pfizer and BioNTech's influenza, COVID-19, and related combination mRNA vaccines from the start of 2025.
GSK plc (GSK) Q2 2025 Earnings Call Transcript
GSK plc (NYSE:GSK ) Q2 2025 Earnings Conference Call July 30, 2025 7:00 AM ET Company Participants Deborah Jayne Waterhouse - CEO of ViiV Healthcare & President of Global Health Emma Natasha Walmsley - CEO & Director Julie Belita Brown - CFO & Executive Director Luke V. Miels - Chief Commercial Officer Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants James Daniel Gordon - JPMorgan Chase & Co, Research Division Kerry Ann Holford - Joh.
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
GSK may have numbers may have been flattered by order timing, says bank
GSK PLC (LSE:GSK, NYSE:GSK) delivered a strong set of second-quarter results, beating expectations on sales, profits, and earnings per share, and raised its guidance to the top end of its previous range. However, UBS analysts caution that much of this outperformance was driven by timing effects, such as early HIV medicine orders and stock builds, particularly in France for the Shingrix vaccine, which are likely to reverse later in the year.
